Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2010
09/14/2010US7794723 treatment or prophylaxis of cancer using proteins or peptides that elicit T cell mediated immunity; vaccination
09/14/2010US7794722 Natural killer T-cell agonists; vaccines; antigen presenting cells
09/14/2010US7794715 T-cell immune response cDNA 7 (TIRC7) antagonist; rheumatoid arthritis; comprising all three complementarity determining regions (CDRs) of the VH and all three complementarity determining regions (CDRs) of the VL variable regions
09/14/2010US7794703 Method for production and delivery of a protein in vivo
09/14/2010US7794700 conjugates containing more than one VLA-4 inhibiting compound covalently attached to a bio-compatible polymer, such as polyethylene glycol; useful in treatment of inflammatory diseases such as asthma, Alzheimer's disease, atherosclerosis, AIDS, dementia, diabetes
09/14/2010US7794699 Nano-structured blood substitutes
09/14/2010US7794698 generating change in cellular process of target cell of multicellular organism resulting in death of target cell by contacting target cell with solid buffer comprising a sulfonated tetrafluoroethylene copolymer so as to alter an intracellular pH value in at least a portion of target cell; cancer therapy
09/14/2010US7794697 kit for enhancing regeneration of lens cells in a mammal after endocapsular extraction, comprising an injectable polysiloxane polymer lens material and a visoelastic material which is a cross-linked hyaluronic acid and hyaluronidase
09/14/2010US7794696 Made from divinyl ethers and diols that may be dimethylol terminated polyamines, polyamides or dendrimers; may be reacted with polynucleotides to form complexes for cell transfection
09/14/2010CA2633573C Inhibition of tau-tau-association
09/14/2010CA2601600C Substituted aryl 1,4-pyrazine derivatives
09/14/2010CA2594789C New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
09/14/2010CA2541292C Vegetable oil formulations for retinoid-containing soft gelatin capsules
09/14/2010CA2536144C Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
09/14/2010CA2531853C Pharmaceutical formulation comprising levothyroxine sodium
09/14/2010CA2521325C Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
09/14/2010CA2509796C Process for modifying drug crystal formation
09/14/2010CA2487211C Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
09/14/2010CA2479353C N-substituted benzothiophenesulfonamide derivative
09/14/2010CA2472335C Geranyl compounds
09/14/2010CA2464151C Ribavirin syrup formulations
09/14/2010CA2458744C Anticancer agents and preparation method of the same
09/14/2010CA2454786C Pharmaceutical composition comprising (-)-secoisolariciresinol
09/14/2010CA2443623C A jasmonate pharmaceutical composition for treatment of cancer
09/14/2010CA2441501C Rho-kinase inhibitors
09/14/2010CA2434834C 6-substituted pyrido-pyrimidines
09/14/2010CA2432009C Pharmaceutical preparations comprising a salt of an antibiotic and an antiphlogistic and use thereof
09/14/2010CA2422805C Retinoids for the treatment of emphysema
09/14/2010CA2416990C Nutritional composition
09/14/2010CA2415558C Acid addition salts of hydropyridine derivatives
09/14/2010CA2410965C Method of stimulating hair growth
09/14/2010CA2409715C .beta.-carboline derivatives useful as inhibitors of phosphodiesterase
09/14/2010CA2401757C Novel fatty acid analogues
09/14/2010CA2399395C Arginine mimetics as factor xa inhibitors
09/14/2010CA2394276C Serine protease inhibitors
09/14/2010CA2393720C Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
09/14/2010CA2388979C Treatment or prevention of hypotension and shock with use of an imidazole derivative
09/14/2010CA2376159C Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method
09/14/2010CA2354210C Indole derivatives and their use as medicaments
09/14/2010CA2347913C Oral administration of adenosine analogs
09/14/2010CA2320202C Agents and methods for protection, treatment and repair of connective tissue
09/14/2010CA2294711C Novel polymeric compositions
09/14/2010CA2289093C Use of melatonin for preparing medicaments for treating circadian rhythm phase disorders
09/14/2010CA2277911C Compounds and their combinations for the treatment of influenza infection
09/14/2010CA2262014C Adipogenic differentiation of human mesenchymal stem cells
09/14/2010CA2261666C Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
09/14/2010CA2261345C Feline polynucleotide vaccine formula
09/14/2010CA2087883C Beta-alethine use in cell culture and therapy
09/13/2010CA2658076A1 Metallic ion chelating agents, method for producing them and use of same
09/10/2010WO2010102286A2 Proteasome inhibitors having chymotrypsin-like activity
09/10/2010WO2010102281A2 Inhibitors of anaphase promoting complex activity
09/10/2010WO2010102267A2 Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
09/10/2010WO2010102252A1 Oral dosage forms having a high loading of a gabapentin prodrug
09/10/2010WO2010102248A2 Molecular tweezers for the treatment of amyloid-related diseases
09/10/2010WO2010102245A1 Solid dispersion comprising resveratrol
09/10/2010WO2010102219A1 Methylenedioxybenzo [i] phenanthridine derivatives used to treat cancer
09/10/2010WO2010102218A1 Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
09/10/2010WO2010102216A2 Enhancing coagulation or reducing fibrinolysis
09/10/2010WO2010102214A2 Method and composition for modulating canonical wnt pathway using folate and inositol
09/10/2010WO2010102192A2 Non-steroidal anti-inflammatory ophthalmic compositions
09/10/2010WO2010102183A1 Methods of enhancing peroxide activity
09/10/2010WO2010102158A1 Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia
09/10/2010WO2010102120A2 Methods and compositions to diagnose pain
09/10/2010WO2010102095A2 Kinase protein binding inhibitors
09/10/2010WO2010102078A1 Enhanced bimatoprost ophthalmic solution
09/10/2010WO2010102071A1 Sustained release oral dosage forms of an r-baclofen prodrug
09/10/2010WO2010102066A1 Dextran polymer powder for inhalation administration of pharmaceuticals
09/10/2010WO2010102031A2 Methods for treating ocular inflammatory diseases
09/10/2010WO2010102003A2 Alkylsulfonyl-2,3-dihydrospiro[indene-1,4'-piperidine] analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
09/10/2010WO2010101994A2 Gene fusion targeted therapy
09/10/2010WO2010101973A1 Fungicidal pyrazoles
09/10/2010WO2010101967A2 Phosphothiophene and phosphothiazole hcv polymerase inhibitors
09/10/2010WO2010101964A2 Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell
09/10/2010WO2010101949A1 8-substituted quinolines and related analogs as sirtuin modulators
09/10/2010WO2010101888A2 Methods and compositions for treatment of tumor metastasis
09/10/2010WO2010101849A1 N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
09/10/2010WO2010101798A1 A topical composition for the treatment of pseudofolliculitis barbae having improved shelf life
09/10/2010WO2010101734A1 Combination cancer therapy with an akt inhibitor and other anticancer agents
09/10/2010WO2010101724A1 Imidazole derivatives useful as modulators of faah and as faah imaging agents
09/10/2010WO2010101649A2 Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
09/10/2010WO2010101622A1 Lung cancer treatment
09/10/2010WO2010101587A1 Use of hypoxanthine for promotion of neuronal outgrowth
09/10/2010WO2010101537A1 Pharmaceutical composition of alendronate and a calcium salt combined in a single dosage form
09/10/2010WO2010101353A2 Composition containing human serum albumin-timp-2 fusion protein and anti-cancer drug for preventing or treating cancer
09/10/2010WO2010101331A1 External use skin composition which suppresses skin aging
09/10/2010WO2010101302A1 Thienopyrimidine as cdc7 kinase inhibitors
09/10/2010WO2010101249A1 Method for enhancing function of t cell
09/10/2010WO2010101248A1 Cell proliferation inhibitor and method for screening same
09/10/2010WO2010101247A1 Cyclohexane derivative having npy y5 receptor antagonism
09/10/2010WO2010101246A1 Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism
09/10/2010WO2010101230A1 Quinoxaline compounds
09/10/2010WO2010101226A1 Nucleic acid complex and nucleic acid-delivering composition
09/10/2010WO2010101178A1 Amino acid-conjugated cyanoacrylate polymer particles
09/10/2010WO2010101164A1 Pyridine derivative
09/10/2010WO2010101128A1 Amide compound
09/10/2010WO2010101127A1 Indole compound
09/10/2010WO2010101115A1 Package of solid pharmaceutical preparation
09/10/2010WO2010101061A1 Nucleoside-type antibiotic derivative
09/10/2010WO2010100933A1 Anti-obesity agent and diabetes-ameliorating agent
09/10/2010WO2010100686A1 Combination use of cholestanol derivative
1 ... 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 ... 7860